Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

NCT03042221 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Carcinoma of Lung, TNM Stage 4
Non-Small Cell Lung Cancer
EGFR Gene Mutation
ALK Gene Mutation
ROSE Cluster 1
BRAF V600E

Sponsor

University of Colorado, Denver